A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
Status:
Completed
Trial end date:
2020-12-23
Target enrollment:
Participant gender:
Summary
This proof of concept study will take place in the US and other countries in approximately 15
clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19
infection who have developed pneumonia and require supplemental oxygen. 20 patients will
receive opaganib in addition to standard of care twice each day for 14 days. 20 will receive
matching placebo in addition to standard of care unless the patient has been discharged from
the hospital without requiring supplemental oxygen, in which case study drug will only be
administered for 10 days. All participants will be followed up for 4 weeks after their last
dose of study drug.